Madison have reported a new approach to forming carbon-nitrogen bonds, a critical step in the synthesis of amines widely used ...

For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...

Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease ...

Aaron Wenger is a senior director and principal scientist at Pacific Biosciences, where he oversees the long-read sequencing ...

A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis ...

All Opinion and interviews articles in Drug Target Review ...

The acquisition brings forward a dual-payload antibody-drug conjugate platform originally developed at UTHealth Houston’s McGovern Medical School. The acquisition brings forward a dual-payload ADC ...

New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both ...

Join this webinar to hear from a distinguished panel of translational leaders as they discuss how N-of-1 breakthroughs can be transformed into scalable genetic medicine platforms to enable broader ...

Tackle the most challenging drug targets with a new, fully automated workflow: Isolate membrane proteins in their native 3D structure in as little as three hours with minimal hands-on time, and learn ...

Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery. Drug discovery ...

Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy. Despite ...